Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Roberta, Maltoni"'
Autor:
Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravaccini
Publikováno v:
Biomedicines, Vol 12, Iss 10, p 2183 (2024)
Background: Patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) generally receive hormonal therapy (HT) combined with CDK4/6 inhibitors (CDK4/6i). Despite this treatment, resistance mechanisms to CDK4/6i emerge and the
Externí odkaz:
https://doaj.org/article/b4f6e5029c6b49319727b60fcd9c8bfa
Autor:
Roberta Maltoni, Andrea Roncadori, William Balzi, Massimiliano Mazza, Fabio Nicolini, Michela Palleschi, Paola Ulivi, Sara Bravaccini
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 498 (2024)
Background: Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors have changed the therapeutic management of hormone receptor-positive (HR+) metastatic breast cancer (mBC) by targeting the cell cycle machinery and overcoming endocrine resistance
Externí odkaz:
https://doaj.org/article/25d2bd4c7187465ba0c974d9e4b44c1d
Autor:
Michela Palleschi, Andrea Prochowski Iamurri, Emanuela Scarpi, Marita Mariotti, Roberta Maltoni, Francesca Mannozzi, Domenico Barone, Giovanni Paganelli, Michela Casi, Emanuela Giampalma, Ugo De Giorgi, Andrea Rocca
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Body composition parameters (BCp) have been associated with outcome in different tumor types. However, their prognostic value in patients with HER2-positive metastatic breast cancer (BC) receiving first line treatment with dual anti-HER2 ant
Externí odkaz:
https://doaj.org/article/491eb08b4bc644f5bf11ddfefef2efc2
Autor:
Roberta Maltoni, William Balzi, Tania Rossi, Francesco Fabbri, Sara Bravaccini, Maria Teresa Montella, Ilaria Massa, Lucia Bertoni, Fabio Falcini, Mattia Altini
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 433-438 (2022)
The risk of relapse for early breast cancer (BC) patients persists even after decades and to date, no specific and sensitive effective circulating biomarker for recurrence prediction has been identified yet. The international guidelines do not recomm
Externí odkaz:
https://doaj.org/article/bfdd26a08f7c46bbbf80dabff4687db6
Autor:
Sara Bravaccini, Fabio Nicolini, Michele Zanoni, Anna Gaimari, Claudio Cerchione, Roberta Maltoni, Francesca Pirini, Lucia Mazzotti, Michela Cortesi, Sara Ravaioli, Maria Maddalena Tumedei, Massimiliano Mazza
Publikováno v:
Translational Oncology, Vol 26, Iss , Pp 101541- (2022)
Zhang et al. reported the impact of different risk factors and comorbidities in COVID-19 lethality. The authors observed that the odds of dying by COVID-19 in cancer patients decrease with age and cancer becomes a non-significant factor above 80 year
Externí odkaz:
https://doaj.org/article/5f27b11055b943d494e3bc8c52f95648
Autor:
Sara Ravaioli, Roberta Maltoni, Barbara Pasculli, Paola Parrella, Anna Maria Giudetti, Daniele Vergara, Maria Maddalena Tumedei, Francesca Pirini, Sara Bravaccini
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle specifically AR-positive BC patients. The prognostic and predictive
Externí odkaz:
https://doaj.org/article/b67955f818b24cc7a58287a220eb2ff7
Autor:
Roberta Maltoni, Sara Ravaioli, Giuseppe Bronte, Massimiliano Mazza, Claudio Cerchione, Ilaria Massa, William Balzi, Michela Cortesi, Michele Zanoni, Sara Bravaccini
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101300- (2022)
Ma and colleagues reported in their study on 12,004 elderly patients published on Breast J. 2020, that adjuvant chemotherapy was not associated with overall survival. Given the toxicities associated with systemic treatments, caution recommendation or
Externí odkaz:
https://doaj.org/article/48243069127b4c598fed7ca309fde0fd
Autor:
Erika Bandini, Tania Rossi, Emanuela Scarpi, Giulia Gallerani, Ivan Vannini, Samanta Salvi, Irene Azzali, Mattia Melloni, Sara Salucci, Michela Battistelli, Patrizia Serra, Roberta Maltoni, William C. Cho, Francesco Fabbri
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Breast cancer (BC) is the most commonly diagnosed malignant tumor in women worldwide, and the leading cause of cancer death in the female population. The percentage of patients experiencing poor prognosis along with the risk of developing metastasis
Externí odkaz:
https://doaj.org/article/a2883136b93b4a32a4c6096fa762fe88
Autor:
Sara Bravaccini, Giuseppe Bronte, Elisabetta Petracci, Maurizio Puccetti, Manolo D’Arcangelo, Sara Ravaioli, Maria Maddalena Tumedei, Roberta Maltoni, Angelo Delmonte, Federico Cappuzzo, Lucio Crinò
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Programmed death ligand 1 (PD-L1) is an immune checkpoint with a role in cancer-related immune evasion. It is a target for cancer immunotherapy and its expression is detected for the use of some immune checkpoint inhibitors in advanced non-small cell
Externí odkaz:
https://doaj.org/article/db302667216f4985b2e27f223631df39
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Externí odkaz:
https://doaj.org/article/116db8dd99f7471ead9c3ec56c57a494